Common use of Discovery Phase Clause in Contracts

Discovery Phase. (a) ABX shall provide AZ with reasonable research quantities of each Research Antibody as specified in the applicable Research Program Work Plan, at ABX’s sole cost and expense, in order for AZ to assess such Antibody and perform its activities under the applicable Research Program and exercise its rights under Article 2. Notwithstanding the foregoing, AZ shall have the right to reasonably request additional research quantities of an Antibody, beyond those quantities set forth in the Research Program Work Plan, for the sole purpose of performing activities outside of the Research Programs that are directed towards designating a Candidate Drug, but not for the purpose of furthering any other AZ activities. If AZ reasonably requests additional research quantities of an Antibody for such purpose, then ABX, at AZ’s sole cost and expense, shall be responsible for manufacturing and supplying such additional research quantities for such purpose. ABX, at its sole cost and expense, shall be responsible for such Antibody scale up activities as are necessary to complete the activities set forth in the Research Programs. If AZ requests additional quantities of any Antibodies as permitted under this Section 7.2.1(a) and ABX does not have sufficient uncommitted quantities available, ABX shall, at its sole cost and expense, provide AZ with the cell line for each such Antibody to enable AZ to produce such Antibody for such purposes. (b) Except as otherwise described in Section 7.2.1(a) and as provided in Sections 7.5, 7.6 and 7.13, ABX, at AZ’s sole cost and expense subject to Section 7.13, shall be responsible for all process development and manufacturing activities (including cell line development and scale up) required to be conducted, prior to the designation of a Candidate Drug, in accordance with the Process Science/Clinical Manufacture Agreement.

Discovery Phase. (a) ABX shall provide AZ with reasonable research quantities of each Research Antibody as specified in the applicable Research Program Work Plan, at ABX’s sole cost and expense, in order for AZ to assess such Antibody and perform its activities under the applicable Research Program and exercise its rights under Article 2. Notwithstanding the foregoing, AZ shall have the right to reasonably request additional research quantities of an Antibody, beyond those quantities set forth in the Research Program Work Plan, for the sole purpose of performing activities outside of the Research Programs that are directed towards designating a Candidate Drug, but not for the purpose of furthering any other AZ activities. If AZ reasonably requests additional research quantities of an Antibody for such purpose, then ABX, at AZ’s sole cost and expense, shall be responsible for manufacturing and supplying such additional research quantities for such purpose. ABX, at its sole cost and expense, shall be responsible for such Antibody scale up activities as are necessary to complete the activities set forth in the Research Programs. If AZ requests additional quantities of any Antibodies as permitted under this Section 7.2.1(a) and ABX does not have sufficient uncommitted quantities available, ABX shall, at its sole cost and expense, provide AZ with the cell line for each such Antibody to enable AZ to produce such Antibody for such purposes. (b) Except as otherwise described in Section 7.2.1(a) and as provided in Sections 7.5, 7.6 7.5 and 7.13, ABX, at AZ’s sole cost and expense subject to Section 7.13, shall be responsible for all process development and manufacturing activities (including cell line development and scale up) required to be conducted, prior to the designation of a Candidate Drug, in accordance with the Process Science/Clinical Manufacture Agreement.